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INTRODUCTION 
 
  
 Breast cancer, which is the most common malignancy in women was 
found to have association with oestrogen and progesterone. The discovery of 
oestrogen receptor and progesterone receptor produced vast changes in the 
management of cancer breast. It is an important prognostic marker  on treating   
patient with carcinoma breast we are often found to how dilemma of how to 
identify those patients  who are likely to most benefit from hormonal treatment. 
Oestrogen and progesterone receptor rich tumors respond well to hormone 
therapy. Tumors negative to hormone receptor respond well to chemotherapy. 
oestrogen and progesterone receptor status is the most important indicator in 
predicting response of advanced breast cancer.  
     
 Role of oestrogen  and progesterone    in development of breast  
Before puberty the breast is composed primarily of dense fibrous stroma and 
scattered ducts  lined with epithelium. In the breast Hormone dependent 
maturation entails increase deposition of fat, formation of new ducts why 
branching and elongation, first appearance of lobular units. This process of 
growth  and cell division is under the control of oestrogen, progesterone, 
adrenal hormones, bigotry hormones on the tropical effects of insulin and 
thyroid hormone.  influence on breast is oestrogen.  the initial immaturity of the 
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hypothalamic pitutary axis results in the anovulatory cycles for the first 1 to 2 
years after mensus begin, subjecting the breast to effects of unopposed 
oestrogen and progesterone. It is during this period of unopposed oestrogen 
stimulation , considered an oestrogen window that the ductal growth phase 
occurs. 
 
        A potent mamogen, oestrogen primary stimulates ductal growth but also 
increases fat deposition and contributes to later phase of development. Impaired 
ductal growth have been demonstrated in what people lacking functional gene 
for the oestrogen receptor and progesterone receptor. Oestrogen receptor  is 
thought to be the key mediator of oestrogen effects and in humans has only be 
documented in luminal epithelium. 
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Epidemiology of breast cancer 
    
 Insurance rates of best cancer increased in most countries through 1990s. 
After 1990 where was overall increase in insurance rates of approximately. 5 % 
annually recent data from SEER program reveal the decline in breast cancer 
incidence over the past decade and this is widely attributed to decrease use of 
hormone replacement therapy. 
  
      Breast cancer burden has well defined variations by geography, regional 
lifestyle and racial or ethnic background. In general both breast cancer 
incidence and mortality are relatively lower among the female  populations of 
Asia and Africa .  in contrast european and North American women and women 
from heavily industrialized or westernized countries have a substantially higher 
breast cancer burden. These  International patterns are mirrored in breast cancer 
incidence and mortality rates. 
  
     Although often the factors that influence breast cancer incidence main 
Vary from doors that affect mortality. Incidence rates are heavily weighted with 
women who begin childbearing at young age and who often how multiple 
pregnancy is followed  By prolonged lactation.  
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   Breast cancer mortality rate should be lower in population that have 
lower insurance. But the mortality burden will simultaneously be adversely 
affected by the absence of screening programs for early detection and 
diminished access to multidisciplinary cancer treatment programs these features 
are likely to account much of the disproportionate mortality risk that are seen in 
underdeveloped Nations. 
 
  Signs and symptoms of breast cancer.  
1. Mass or swelling in the breast    
2.  ulceration or fungating breast  .  
3.   nipple ulceration. 
4.   nipple retraction. 
5.  Discharge  
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REVIEW OF LITERATURE 
 
 The value of adjuvant chemotherapy in treating breast cancer is well 
documented. The idea of neoadjuvant chemotherapy has been recently applied 
to breast cancer treatment and studies have shown the efficacy of neoadjuvant 
chemotherapy in down-staging the primary tumor. Before giving neoadjuvant 
chemotherapy hormone receptor status is analysed , based on which NAC is 
given. 
  
 The Milan Group, using a combination of doxorubicin and vincristine, 
achieved an 80% response rate with 15% of patients attaining complete clinical 
response. Tumor shrinkage by the neoadjuvant chemotherapy can be easily 
monitored clinically both by physicians and patients. For physicians, 
continuation of treatment is reasonably determined based on efficacy. For 
patients, compliance with the scheduled courses of chemotherapy is increased 
because they, themselves, experience the efficacy, which helps them mentally to 
overcome the unpleasant adverse effects. The pathological response to the 
neoadjuvant chemotherapy provides reliable prognostic information with 
increased overall (OS) and disease free survival (DFS). 
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 The use of neoadjuvant chemotherapy in treating breast cancer has shown 
efficacy in downstaging primary tumors, and allows breast conservative surgery 
to be performed instead of mastectomy. This study aims to evaluate patterns of 
clinical and pathological response and hormone receptor status after 
neoadjuvant chemotherapy in patients with locally advanced breast cancer. 
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EMBRYOLOGY 
 At the fifth or sixth week of fetal development, two ventral bands of 
thickened ectoderm (mammary ridges, milk lines) are evident in the embryo. In 
most mammals, paired breasts develop along these ridges, which extend from 
the base of the forelimb (future axilla) to the region of the hind limb (inguinal 
area). These ridges are not prominent in the human embryo and disappear after 
a short time, except for small portions that may persist in the pectoral region. 
Accessory breasts (poly mastia ) or accessory nipples (polythelia) may occur 
along the milk line ,when normal regression fails. Each breast develops when 
an ingrowth of ectoderm forms a primary tissue bud in the mesenchyme. The 
primary bud, in turn, initiates the development of 15 to 20 secondary buds. 
Epithelial cords develop from the secondary buds and extend into the 
surrounding mesenchyme.  
 Major (lactiferous) ducts develop, which open into a shallow mammary 
pit. During infancy, a proliferation of mesenchyme transforms the mammary pit 
into a nipple. If there is failure of a pit to elevate above skin level, an inverted 
nipple results. This congenital malformation occurs in 4% of infants. At birth, 
the breasts are identical in males and females, demonstrating only the presence 
of major ducts. Enlargement of the breast may be evident and a secretion, 
referred to as witch's milk, may be produced. These transitory events occur in 
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response to maternal hormones that cross the placenta 
 The breast remains undeveloped in the female until puberty, when it 
enlarges in response to ovarian estrogen and progesterone, which initiate 
proliferation of the epithelial and connective tissue elements. However, the 
breasts remain incompletely developed until pregnancy occurs. Absence of the 
breast (amastia) is rare and results from an arrest in mammary ridge 
development that occurs during the sixth fetal week. Poland's syndrome 
consists of hypoplasia or complete absence of the breast, costal cartilage 
and rib defects, hypoplasia of the subcutaneous tissues of the chest wall, and 
brachysyndactyly. Breast hypoplasia also may be iatrogenically induced before 
puberty by trauma, infection, or radiation therapy. Symmastia is a rare anomaly 
recognized as webbing between the breasts across the midline. Accessory 
nipples (polythelia) occur in <1% of infants and may be associated with 
abnormalities of the urinary tract (renal agenesis and cancer), abnormalities of 
the cardiovascular system (conduction disturbances, hypertension, congenital 
heart anomalies), and other conditions (pyloric stenosis, epilepsy, ear 
abnormalities, arthrogryposis). Supernumerary breasts may occur in any 
configuration along the mammary milk line but most frequently occur between 
the normal nipple location and the symphysis pubis.  Turner's syndrome 
(ovarian agenesis and dysgenesis) and Fleischer's syndrome (displacement of 
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the nipples and bilateral renal hypoplasia) may have polymastia as a 
component. Accessory axillary breast tissue is uncommon and usually is 
bilateral 
 The breast is composed of 15 to 20 lobes, which are each composed of 
several lobules. Fibrous bands of connective tissue travel through the breast 
(Cooper's suspensory ligaments), insert perpendicularly into the dermis, and 
provide structural support. The mature female breast extends from the level of 
the second or third rib to the inframammary fold at the sixth or seventh rib. It 
extends transversely from the lateral border of the sternum to the anterior 
axillary line. The deep or posterior surface of the breast rests on the fascia of the 
pectoralis major, serratus anterior, and external oblique abdominal muscles, and 
the upper extent of the rectus sheath. The retromammary bursa may be 
identified on the posterior aspect of the breast between the investing fascia of 
the breast and the fascia of the pectoralis major muscles. The axillary tail of 
Spence extends laterally across the anterior axillary fold. The upper outer 
quadrant of the breast contains a greater volume of tissue than do the other 
quadrants. The breast has a protuberant conical form. The base of the cone is 
roughly circular, measuring 10 to 12 cm in diameter. Considerable variations in 
the size, contour, and density of the breast are evident among individuals. The 
nulliparous breast has a hemispheric configuration with distinct flattening above 
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the nipple. With the hormonal stimulation that accompanies pregnancy and 
lactation, the breast becomes larger and increases in volume and density, 
whereas with senescence, it assumes a flattened, flaccid, and more pendulous 
configuration with decreased volume. 
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BREAST 
  The breasts form a secondary sexual feature of females and are a source 
of nutrition for the neonate. In young adult females, each breast is a rounded 
eminence largely lying within the superficial fascia anterior to the upper thorax 
but spreading laterally to a variable extent. Breast shape and size depend on 
genetic, racial and dietary factors and on the age, parity and menopausal status 
of the individual. Breasts may be hemispherical, conical, variably pendulous, 
piriform or thin and flattened. In the adult female, the base of the breast, i.e. its 
attached surface, extends vertically from the second or third to the sixth rib, and 
in the transverse plane from the sternal edge medially almost to the mid-axillary 
line laterally. The superolateral quadrant is prolonged towards the axilla along 
the inferolateral edge of pectoralis major, from which it projects a little, and 
may extend through the deep fascia up to the apex of the axilla (the axillary tail 
of Spence). The trunk superficial fascial system splits to enclose the breast to 
form the anterior and posterior lamellae. Posterior extensions of the superficial 
fascial system connect the breast to the pectoralis fascia, part of the deep fascial 
system. The inframammary crease is a zone of adherence of the superficial 
fascial system to the underlying chest wall at the inferior crescent of the breast. 
The breast lies on the deep pectoral fascia, which in turn overlies pectoralis 
major and serratus anterior superiorly and external oblique and its aponeurosis 
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inferiorly, as the latter forms the anterior wall of the rectus sheath. Between the 
breast and the deep fascia, the loose connective tissue in the ‘sub mammary 
space’ allows the breast some degree of movement on the deep pectoral fascia. 
Nipple areola complex 
 The epidermis of the nipple-areola complex is pigmented and is variably 
corrugated. During puberty, the pigment becomes darker and the nipple 
assumes an elevated configuration. During pregnancy, the areola enlarges and 
pigmentation is further enhanced. The areola contains sebaceous glands, sweat 
glands, and accessory glands, which produce small elevations on the surface of 
the areola (Montgomery's tubercles). Smooth muscle bundle fibers, which lie 
circumferentially in the dense connective tissue and longitudinally along the 
major ducts, extend upward into the nipple, where they are responsible for the 
nipple erection that occurs with various sensory stimuli. The dermal papilla at 
the tip of the nipple contains numerous sensory nerve endings and Meissner's 
corpuscles. This rich sensory innervation is of functional importance, because 
the sucking of the infant initiates a chain of neurohumoral events that results in 
milk letdown 
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Axilla: 
 The anatomical boundaries of the axilla represent a pyramidal 
compartment located between the upper extremity and the thoracic wall; this 
structure has four boundaries inclusive of a base and an apex. The curved 
oblong base consists of axillary fascia. The apex of the axilla represents an 
aperture that extends into the posterior triangle of the neck via the cervico 
axillary canal. Most structures that course between the neck and the upper 
extremity enter this anatomic passage. which is bounded anteriorly by the 
clavicle. medially by the first rib. and posteriorly by the scapula. The anterior 
wall of the axilla is composed of the pectoralis major and minor muscles and 
their associated fasciae. The posterior wall is formed primarily of the 
subscapularis muscle, located on the anterior surface of the scapula, and to a 
lesser extent by the teres major and latissimus dorsi muscles. The lateral wall of 
the axilla is the bicipital groove, a thin strip of condensed muscular tissue 
between the insertion of the musculature of the anterior and posterior 
compartments. The medial wall is composed of the serratus anterior muscle. 
The fascia of the pectoralis major and minor muscles are evident in two distinct 
planes: The superficial layer, called the pectoral fascia, invests the pectoralis 
major muscle, whereas the deep layer, called the clavi pectoral or costo 
coracoid fascia. Extends from the clavicle to the axillary fascia in the floor of 
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the axilla and encloses the subclavius and the pectoralis minor muscle. The 
costo coracoid membrane represents the upper portion of the clavi pectoral 
fascia and is pierced by the cephalic vein, the lateral pectoral nerve, and 
branches of the thoraco acromial trunk. The medial pectoral nerve does not 
penetrate the costo coracoid membrane, but enters the deep surface of the 
pectoralis minor and passes through the anterior investing fascia of the 
pectoralis minor to innervate the pectoralis major muscle. Caudal portions of 
the clavi pectoral fascia, which are anatomically inferior to the pectoralis minor 
are sometimes referred to as the suspensory ligament of the axilla or the coraco 
axillary fascia. Many surgeons refer to this anatomic landmark as Halsted's 
ligament, which represents a dense condensation of the clavi pectoral fascia that 
extends from the medial aspect of the clavicle, attaches to the first rib, and 
invests the subclavian artery and vein as each traverse the first rib. Within the 
axilla are the great vessels and nerves of the upper extremity, which, together 
with the other a:xillary contents, are encircled by loose connective tissue. These 
vessels and nerves are anatomically contiguous and are enclosed within an 
investing layer of fascia referred to as the axillary sheath.  
 The axillary artery can be divided into three anatomical segments within 
the axilla proper: 
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1. Located medial to the pectoralis minor muscle, the first segment gives rise to 
one branch, the suprior thoracic, which supplies the upper thoracic wall 
inclusive of the first and second intercostal spaces. 
 
2. The second segment of this artery, located immediately posterior to the 
pectoralis minor, gives rise to two branches, the thoraco acromial trunk and the 
lateral thoracic artery. Pectoral branches of the thoraco acromial and lateral 
thoracic arteries supply the pectoralis major and minor muscles. Identification 
of these vessels during surgical dissection of the axilla is imperative to provide 
safe conduct of the procedure. The lateral thoracic artery gives origin to the 
lateral mammary branches. 
3. The third segment of this vessel, located lateral to the pectoralis minor 
muscle, gives rise to three branches. These include the anterior and posterior 
humeral circumflex artery that supply the upper arm, and the subscapular 
artery, which is the largest branch within the axilla. After a short course, the 
subscapular artery gives origin to its terminal branches, the subscapular 
circumflex and the thoracodorsal arteries. The thoracodorsal artery, which 
courses with its corresponding nerve and vein, crosses the subscapularis 
muscle, providing its substantial blood supply, as well as that of the serratus 
anterior and latissimus dorsi muscles. 
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Tributaries of the axillary vein follow the course of the branches of the axillary 
artery, usually in the form of venae comitantes, paired veins that follow the 
course of the artery. The cephalic vein passes in the groove between the deltoid 
and pectoralis major muscles, and thereafter enters the axillary vein after 
piercing the clavipectoral fascia. Anatomically, the axillary artery is contiguous 
with various portions of the brachial plexus throughout its course in the axilla. 
The cords of the brachial plexus are named according to their structural and 
positional relationship with the axillary artery-medial, lateral, and posterior 
rather than their anatomic position in the axilla or on the chest wall. 
  The three nerves of principal interest to surgeons that are located in the 
axilla: The long thoracic nerve, located on the medial wall of the axilla, arises 
in the neck from the fifth, sixth, and seventh cervical roots (C5, C6, and C7) 
with entry in the axilla via the cervicoaxillary canal. This medially placed nerve 
lies on the lateral most surface of the serratus anterior muscle and is invested by 
the serratus fascia such that it might be accidentally divided together with 
resection of the fascia during surgical dissection (sampling) of lymphatics of the 
axilla. The long thoracic nerve, although diminutive in size, courses a 
considerable anatomic distance to supply the serratus anterior muscle, injury or 
division of this nerve results in the '"winging of scapula" deformity with 
denervation of the muscle group and the inability to provide shoulder fixation. 
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The thoracodorsal nerve takes origin from the posterior cord of the brachial 
plexus and innervates the laterally placed latissimus dorsi muscle. Injury or 
division is inconsequential to primary shoulder function; however, preservation 
of this nerve is essential to provide transfer survival and motor function 
preservation for the myocutaneous flap used for the latissimus dorsi 
musculocutaneous reconstruction. The intercostobrachial nerve is formed by 
the merging of the lateral cutaneous branch of the second intercostal nerve with 
the medial cutaneous nerve of the arm; this nerve provides sensory innervation 
of the skin of the apex and lateral axilla and the upper medial and inner aspect 
of the arm. A second intercostobrachial nerve may sometimes form an anterior 
branch of the third lateral cutaneous nerve. 
 
Blood Supply of Breast: 
 Blood supply to the mammary gland is derived from perforating branches 
of the internal mammary artery, lateral branches of the posterior intercosta1 
arteries, and several branches of the axillary artery. The latter vessels include 
the highest thoracic, lateral thoracic, and pectoral branches of the 
thoracoacromial artery. Branches from the second, third, and fourth anterior 
perforating arteries pass to the breast as medial mammary arteries. The lateral 
thoracic artery branches allow perfusion to the serratus anterior muscle, both 
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the pectoralis muscles, and the subscapularis muscle, and also supply the 
axillary lymphatics and supporting fatty tissues. The posterior intercostal 
arteries give rise to mammary branches in the second, third, and fourth 
intercostal spaces. Although the thoracodorsal branch of the subscapular artery 
does not contribute to the primary blood supply of the breast per se, this vessel 
is intimately associated 
with the central and scapular lymph node groups of the axilla. This fact should 
be taken into consideration during axillary node dissection, as bleeding that is 
difficult to control can result when penetrating branches of this vessel are 
severed. 
 Principal venous outflow of the gland has preferential directional flow 
toward the axilla, with the veins principally paralleling the path of the arterial 
distribution. The superficial venous plexus of mammary parenchyma has 
extensive anastomoses that may be evident through the overlying skin. 
Circumscribing the nipple, superficial veins form an anastomotic circle, the 
circulus venosus. Veins from this circle and from deeper aspects of the gland 
converge to drain blood to the periphery of the breast, and thereafter into 
vessels that terminate in the internal mammary, axillary, and internal jugular 
yeins. Venous return from the gland is derived from three principal groups of 
veins providing drainage of the breast and the thoracic wall and include (a) 
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perforating branches of the internal mammary vein, (b) tributaries of the 
axillary vein, and (c) perforating branches of posterior intercostal veins. The 
posterior intercostal veins lie indirect continuity with the vertebral plexus of 
veins (Batson’s plexus) that surround the vertebrae and extend from the base of 
the skull to the sacrum. Clinically, this plexus may provide an important 
pathway for hematogenous dissemination of breast cancer, and may 
physiologically account for metastases to the skull, vertebrae, pelvic bones, and 
centeral nervous system in the absence of pulmonary metastases. 
 
 
Blood Supply 
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Topography of Breast 
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Breast – Sagittal View 
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INACTIVE AND ACTIVE BREAST 
 
Each lobe of the breast terminates in a major (lactiferous) duct (2 to 4 
mm in diameter), which opens through a constricted orifice (0.4 to 0.7 mm in 
diameter) into the ampulla of the nipple . Immediately below the nipple-areola 
complex, each major duct has a dilated portion (lactiferous sinus), which is 
lined with stratified squamous epithelium. Major ducts are lined with two layers 
of cuboidal cells, Whereas minor ducts are lined with a single layer of columnar 
or cuboidal cells. Myoepithelial cells of ectodermal origin reside between the 
epithelial cells in the basal lamina and contain myofibrils. In the inactive breast, 
the epithelium is sparse and consists primarily of ductal epithelium . In the early 
phase of the menstrual cycle, minor ducts are cord-like with small lumina. With 
estrogen stimulation at the time of ovulation, alveolar epithelium increases in 
height, duct lumina become more prominent, and some secretions accumulate. 
When the hormonal stimulation decreases, the alveolar epithelium regresses. 
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EPIDEMIOLOGY 
“Worldwide, breast cancer is the most common type of cancer and the 
most common cause of cancer-related mortality among women. In women, 
breast cancer accounts for 26% of new cases of cancer and 15% of cancer 
deaths, second only to lung cancer as a cause of cancer-specific death. 
Approximately 1% of breast cancers occur in males and 90% are estrogen 
receptor (ER)-positive. Incidence rates continued to increase until 2002, likely 
reflecting the increase in use of mammographic screening, but recently have 
been reported to be declining. Part of that decline may be due to a decrease in 
the use of postmenopausal hormone replacement therapy. Although incidence 
rates (all races combined) are substantially higher for women age 50 and older 
(375.0 per 100,000) compared with women younger than 50 years (42.5 per 
100,000), approximately 23% of breast cancers are diagnosed in women 
younger than 50 years, because those women represent 73% of the female 
population.” 
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RISK FACTORS 
Dietary and Lifestyle Factors: 
“Observational studies suggested that high-fat diets were associated with higher 
rates of breast cancer than low-fat diets. However, a meta-analysis of eight 
prospective epidemiologic studies failed to identify an association between fat 
intake and breast cancer risk in adult women in developed countries. Consistent 
with these findings, a randomized dietary modification in 48,835 women in the 
Women’s Health Initiative study did not result in a statistically significant 
reduction in breast cancer incidence after 8 years of follow-up. Breast cancer 
risk increases linearly with the amount of alcohol consumed. 
Obesity is associated with both an increased risk of breast cancer development 
in postmenopausal women and increased breast cancer mortality. Women with a 
body mass index of ≥31.1 have a 2.5-fold greater risk of developing breast 
cancer than those with a body mass index of ≤22.6.23 Weight and weight gain 
appear to play an important but complex role in breast cancer risk. 
Environmental Factors: 
 Exposure to ionizing radiation increases breast cancer risk, and the 
increase is particularly marked for exposure at a young age. This pattern has 
been observed in survivors of the atomic bombings, those undergoing multiple 
diagnostic X-ray examinations, and in women receiving therapeutic irradiation. 
25 
 
A markedly increased risk of breast cancer development has been reported in 
women who received mantle irradiation for the treatment of Hodgkin 
lymphoma before age 15 years. 
Hormonal Factors: 
 The development of breast cancer in many women appears to be related 
to female reproductive hormones, particularly endogenous estrogens. Early age 
at menarche, nulliparity or late age at first full-term pregnancy, and late age at 
menopause increase the risk of developing breast cancer. In postmenopausal 
women, obesity and postmenopausal hormone replacement therapy (HRT), both 
of which are positively correlated with plasma estrogen levels and plasma 
estradiol levels, are associated with increased breast cancer risk. Most hormonal 
risk factors have a relative risk (RR) of ≤2 for breast cancer development. 
The age-specific incidence of breast cancer increases steeply with age until 
menopause, and then plateaus. There is substantial evidence that estrogen 
deprivation via iatrogenic premature menopause can reduce breast cancer risk. 
Premenopausal women who undergo oophorectomy without hormone 
replacement have a markedly reduced risk of breast cancer later in life, with an 
increasing magnitude of risk reduction as the age at oophorectomy decreases. 
Data from women with BRCA1 and BRCA2 mutations suggest that early 
oophorectomy has a substantial protective effect on breast cancer risk in this 
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population also. Age at menarche and the establishment of regular ovulatory 
cycles are strongly .ed to breast cancer risk; the total duration of exposure to 
endogenous estrogens seems important. There appears to be a 20% decrease in 
breast cancer risk for each year that menarche is delayed. Of note, hormone 
levels through the reproductive years in women who experience early menarche 
may be higher than in women who undergo a later menarche. Additionally, late 
onset of menarche results in a delay in the establishment of regular ovulatory 
cycles, which may contribute to protective effects. 
 Nulliparous women are at greater risk for the development of breast 
cancer than parous women, with a RR of about 1.4. Breastfeeding, particularly 
for longer duration, lowers the risk of breast cancer diagnosis. The combined 
effects of reproductive history and breastfeeding may account for substantial 
fractions of the difference in breast cancer risk between developed and 
developing nations. 
Familial Factors: 
A family history of breast cancer has long been recognized as a risk factor for 
the disease, but only 5% to 10% of women who develop breast cancer have a 
true hereditary predisposition. Overall, the risk of developing breast cancer is 
increased 1.5-fold to 3 fold if a woman has a mother or sister with breast cancer. 
Mutations in the breast cancer susceptibility genes BRCA1 and BRCA2 are 
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associated with a significant increase in the risk of breast and ovarian 
carcinoma, and account for 5% to 10% of all breast cancers. These mutations 
are inherited in an autosomal dominant fashion and have varying penetrance.” 
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WHO Classification of Tumors of the Breast 
• Epithelial tumors 
o Microinvasive carcinoma 
 
• Invasive breast carcinoma 
o Invasive carcinoma of no special type (NST) 
 Pleomorphic carcinoma 
 Carcinoma with osteoclast like stromal giant cells 
 Carcinoma with choriocarcinomatous features 
 Carcinoma with melanotic features 
o Invasive lobular carcinoma 
 Classic lobular carcinoma 
 Solid lobular carcinoma 
 Alveolar lobular carcinoma 
 Pleomorphic lobular carcinoma 
 Tubulolobular carcinoma 
 Mixed lobular carcinoma 
o Tubular carcinoma 
o Cribiform carcinoma 
o Mucinous carcinoma 
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o Carcinoma with medullary features 
 Medullary carcinoma 
 Atypical medullary carcinoma 
 Invasive carcinoma NST with medullary features 
o Carcinoma with apocrine differentiation 
o Carcinoma with signet ring differentiation 
o Invasive micropapillary carcinoma 
o Metaplastic carcinoma of no special type 
 Low-grade adenosquamous carcinoma 
 Fibromatosis like metaplastic carcinoma 
 Squamous cells carcinoma 
 Spindle cell carcinoma 
 Metaplastic carcinoma with mesenchymal differentiation 
 Chondroid differentiation 
 Osseous differentiation 
 Other types of mesenchymal differentiation 
 Mixed metaplastic carcinoma 
 Myoepithelial carcinoma 
o Rare types 
 Carcinoma with neuroendocrine features 
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 Neuroendocrine tumor, well differentiated 
 Neuroendocrine carcinoma, poorly differentiated 
(small cell carcinoma) 
 Carcinoma with neuroendocrine differentiation 
 Secretory carcinoma 
 Invasive papillary carcinoma 
 Acinic cell carcinoma 
 Mucoepidermoid carcinoma 
 Polymorphous carcinoma 
 Oncocytic carcinoma 
 Lipid rich carcinoma 
 Glycogen rich clear cell carcinoma 
 Sebaceous carcinoma 
 Salivary gland / skin adnexal type tumors 
 Cylindroma 
 Clear cell hidradenoma 
 
• Epithelial-myoepithelial tumors 
o Pleomorphic adenoma 
o Adenomyoepithelioma 
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 Adenomyoepithelioma with carcinoma 
o Adenoid cystic carcinoma 
 
• Precursor lesions 
o Ductal carcinoma in situ 
o Lobular neoplasia 
 Lobular carcinoma in situ 
 Classic lobular carcinoma in situ 
 Pleomorphic lobular carcinoma in situ 
 Atypical lobular hyperplasia 
 
• Intraductal proliferative lesions 
o Usual ductal hyperplasia 
o Columnar cell lesions including flat epithelial atypia 
o Atypical ductal hyperplasia 
 
• Papillary lesions 
o Intraductal papilloma 
 Intraductal papilloma with atypical hyperplasia 
 Intraductal papilloma with ductal carcinoma in sit 
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 Intraductal papilloma with lobular carcinoma in situ 
o Intraductal papillary carcinoma 
o Encapsulated papillary carcinoma 
 Encapsulated papillary carcinoma with invasion 
o Solid papillary carcinoma 
 In situ 
 Invasive 
• Tumors of the nipple 
o Nipple adenoma 
o Syringomatous adenoma 
o Paget disease of the nipple 
 
• Malignant lymphoma 
o Diffuse large B cell lymphoma 
o Burkitt lymphoma 
o T cell lymphoma 
 Anaplastic large cell lymphoma, ALK negative 
o Extranodal marginal-zone B cell lymphoma of MALT-type 
o Follicular lymphoma 
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• Metastatic tumors 
• Tumors of the male breast 
o Gynaecomastia 
o Carcinoma 
 Invasive carcinoma 
 In situ carcinoma 
 
• Clinical patterns 
o Inflammatory carcinoma 
o Bilateral breast carcinoma 
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AJCC STAGING 
 Primary tumor (T) Definitions for classifying the primary tumor (T) are 
the same for clinical and for pathologic classification. If the measurement is 
made by physical examination, the examiner will use the major headings (T1, 
T2, or T3); if other measurements, such as mammographic or pathologic 
measurements, are used, the subsets of T1 can be used. Tumors should be 
measured to the nearest 0.1-cm increment. 
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
Tis Carcinoma in situ 
Tis (DCIS) Ductal carcinoma in situ 
Tis (LCIS) Lobular carcinoma in situ 
Tis (Paget's) 
Paget's disease of the nipple with no tumor (NOTE: Paget's disease associated 
with a tumor is classified according 
to the size of the tumor) 
T1 Tumor 2 cm in greatest dimension 
T1mic Microinvasion 0.1 cm or less in greatest dimension 
T1a Tumor >0.1 cm but not >0.5 cm in greatest dimension 
T1b Tumor >0.5 cm but not >1 cm in greatest dimension 
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T1c Tumor >1 cm but not >2 cm in greatest dimension 
T2 Tumor >2 cm but not >5 cm in greatest dimension 
T3 Tumor >5 cm in greatest dimension 
T4 Tumor of any size with direct extension to (a) chest wall or (b) skin, only as 
described below 
T4a Extension to chest wall, not including pectoralis muscle 
T4b Edema (including peau d'orange), or ulceration of the skin of the breast, or 
satellite skin nodules confined to the same breast 
T4c Both T4a and T4b 
T4d Inflammatory carcinoma 
Regional lymph nodes—Clinical (N) 
NX Regional lymph nodes cannot be assessed (e.g., previously removed) 
N0 No regional lymph node metastasis 
N1 Metastasis to movable ipsilateral axillary lymph node(s) 
N2 Metastases in ipsilateral axillary lymph nodes fixed or matted, or in 
clinically apparenta ipsilateral internal 
mammary nodes in the absence of clinically evident axillary lymph node 
metastasis 
N2a Metastasis in ipsilateral axillary lymph nodes fixed to one another (matted) 
or to other structures 
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N3 Metastasis only in clinically apparenta ipsilateral internal mammary nodes 
and in the absence of clinically evident 
axillary lymph node metastasis; metastasis in ipsilateral infraclavicular lymph 
node(s) with or without axillary lymph node involvement, or in clinically 
apparenta ipsilateral internal mammary lymph node(s) and in the 
presence of clinically evident axillary lymph node metastasis; or metastasis in 
ipsilateral supraclavicular lymph node(s) with or without axillary or internal 
mammary lymph node involvement 
N3a Metastasis in ipsilateral infraclavicular lymph node 
N3b Metastasis in ipsilateral internal mammary lymph nodes(s) and axillary 
lymph node(s) 
N3c Metastasis in ipsilateral supraclavicular lymph node(s) 
M0 No clinical or radiographic evidence of distant metastases 
cM0(i+) No clinical or radiographic evidence of distant metastases, but deposits 
of molecularly or microscopically detected tumor cells in circulating blood, 
bone marrow, or other non-regional nodal tissue that are no larger than 0.2 mm 
in a patient without symptoms or signs of metastases” 
M1 Distant detectable metastases as determined by classic clinical and 
radiographic means and/or histologically proven larger than 0.2 mm” 
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ANATOMIC STAGE/PROGNOSTIC GROUPS: 
Stage 0 Tis N0 M0 
Stage IA T1 N0 M0 
Stage IB T0 
T1 
N1mi 
N1mi 
M0 
Stage  IIA T0 
T1 
T2 
N1 
N1 
N0 
M0 
Stage IIB T2 
T3 
N1 
N0 
M0 
Stage IIIA T0 
T1 
T2 
T3 
T3 
N2 
N2 
N2 
N1 
N2 
M0 
Stage IIIB T4 
T4 
T4 
N0 
N1 
N2 
M0 
Sage IIIC Any T N3 M0 
Sage IV Any T Any N M1 
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 “Inspection of arm and thorax: Edema of the arm may be due to 
lymphatic obstruction of axillary nodes by malignant cells spreading from 
carcinoma breast. Edema begins from distal to proximal and more prominent 
distally (brawny edema). Venous obstruction can also cause edema arm. Here 
edema is more prominent proximally in the arm and is having bluish 
discolouration over the skin. It is commonly due to infiltration and often by 
compression of lymph nodal metastatic disease onto the axillary vein. It needs 
urgent radiotherapy to axilla or chemotherapy otherwise venous gangrene of 
upper limb may develop. Arm edema may be seen after mastectomy also. 
Multiple nodules with skin thickening over the arm and chest wall due to 
carcinomatous infiltration is called as ‘cancer en cuirasse’as it looks like armor 
coat. 
Palpation 
 Normal breast tissue is firm, lobulated with fine nodularity. Often it can 
be soft and smooth also. Palpation is also done between thumb and fingers. All 
quadrants should be palpated along with nipple areola complex and axillary tail 
of Spence. 
 During palpation one should look for raise in temperature over the breast 
(observed in mastitis but also can occur in vascular tumor like medullary 
carcinoma and sarcoma), tenderness, nature of the swelling—its size, shape, 
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extent, surface, margin, consistency (carcinoma is hard/stony hard and 
irregular), fixity to breast tissue (swelling will not have independent/differential 
mobility), fixity to skin (by pinching the skin), fixity to pectoral fascia (by 
tethering), fixity to pectoralis major muscle/serratus anterior muscle/latissimus 
dorsi muscle. Palpate ulcer if present—look for tenderness, its edge and base 
for induration, bleeding on palpation. Nipple and areola should be palpated for 
tenderness, eversion, induration and discharge. 
 Local rise of temperature: It is checked with dorsum of fingers. Breast is 
warm in mastitis and so also sarcomas can be warmer. Aggressive carcinoma 
also can be warm due to increased vascularity. 
Tenderness: Breast is tender to palpate in acute mastitis and abscess. Carcinoma 
is non tender initially but becomes tender once skin is involved or when chest 
wall infiltration occurs. 
Number, size and shape: Carcinoma of breast is solitary; fibro adenosis can be 
multiple. Fibro adenoma is usually solitary but multiple fibro adenomas are 
known to occur occupying entire breast tissue.  
 Opposite breast also can be involved especially in  
fibro adenosis. Size is important in staging the  (T staging) carcinoma breast 
and so it should be measured using a tape (in cm). 
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Margin: Margin is well-defined and regular in fibro adenoma; well-defined and 
irregular in carcinoma; ill-defined in fibro adenosis. 
Surface: It may be nodular or granular or uneven in carcinoma. Smooth surface 
is seen in benign condition like fibro adenoma. 
Consistency: Fibro adenoma is firm swelling; carcinoma is stony hard; fibro 
adenosis is firm or diffuse India rubber consistency. Sarcoma is variable with 
soft or firm or hard in texture. 
Fluctuation: When swelling is soft, fluctuation test is done. It is done by 
examiner standing or sitting behind the patient. Two hands of the examiner are 
placed above the shoulders of the patient. Swelling is held with one hand and 
with index finger of the other hand summit of the swelling is pressed/indented. 
Fluid displacement can be appreciated with yielding of the finger. Cystic 
swelling, localised abscess can be fluctuant.” 
”Fixity of the lump to breast tissue: It is checked by holding the breast tissue 
in one hand and moving the lump in other hand. If lump is fixed to breast tissue, 
then breast tissue moves along the lump. Carcinoma breast is fixed to breast 
tissue. Fibro adenoma shows free  mobility   (differential mobility)  within the 
breast tissue and so is called as ‘breast mouse’. 
Skin tethering can be demonstrated by moving the lump one side. It is due to 
inward puckering of the skin following involvement of the elastic Cooper’s 
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ligament which becomes inelastic. Dimpling of skin appears which can be 
demonstrated by raising the arms above the shoulder level. When skin tethering 
occurs lump can be moved in the arc anywhere without moving the overlying 
skin whereas lump cannot be moved at all without moving the skin in skin 
fixation. 
Fixity to skin: When tumor directly infiltrates the skin, fixity occurs. Here skin 
will not be moved separately over the lump. Skin thickening and hard nodules 
are felt. Peau d’ orange can be better seen by holding the skin between thumb 
and fingers. Whether benign or malignant, when tumor lies beneath the nipple, 
it is fixed to it. But tumor beneath the areola may or may not be fixed to it as it 
depends on presence or absence of infiltration to areola. 
 
Fixity to pectoralis major muscle: It is checked in sitting position. Patient is 
asked to keep her hands on her waist. Lump is moved along the direction of the 
muscle and also perpendicular to the direction of the muscle. Patient is asked to 
hold the hands tightly pressed over the  waist to contract the pectoralis major 
muscle (action of the muscle is flexion of the shoulder) which is confirmed by 
feeling the taut muscle. Lump is again moved along the direction and 
perpendicular to the direction of the muscle. Mobility along the line of muscle 
fibers will be restricted totally if lump is adherent to the pectoralis major 
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muscle. It becomes T3 stage tumor.” 
 
Fixity to latissimus dorsi muscle: It is checked in sitting position with 
examiner standing by the side of the patient. Latissimus dorsi is an extensor of 
the shoulder joint. Initially mobility of the lump is checked and then arm is 
extended against resistance with elbow flexed 90°  to contract the latissimus 
dorsi. If now mobility of the lump is restricted, it confirms that lump is fixed to 
latissimus dorsi muscle 
Fixity to serratus anterior muscle: It is checked by checking the mobility of 
the lump before and after contracting the serratus anterior. Contraction of 
serratus anterior is achieved by pushing both the outstretched hands against 
resistance over the wall or over the examiner’s shoulders and checking for 
restriction of mobility of the lump. It signifies involvement of chest wall—stage 
T4. 
Chest wall fixity: It can be assessed by absence/ presence of mobility of the 
mass; and breast with mass will not fall forward if it is fixed to underlying chest 
wall; and on raising the arm above shoulder breast with mass will not raise 
upward. Chest wall fixity means fixity to ribs and intercostal muscles. 
”Palpation of nipple: It is equally important to palpate the nipple. Tenderness, 
thickening, hardness, mobility should be checked. Tumor underneath nipple is 
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usually fixed to nipple. Retraction of nipple may be confirmed by palpating it. 
Discharge can be better appreciated while palpatin g the lump in the breast or 
other part of breast tissue or nipple itself. Colour, content (serous, blood, pus, 
greenish milk) of the discharge can be found. Discharge should be collected for 
cytology or culture or AFB staining. In retracted nipple, gentle pressing of the 
base of the nipple is done to evert it. If it is due to congenital or of benign 
cause, retracted nipple can be everted by pressing at the base. If retraction is 
due to carcinoma, it cannot be everted at all. Retraction is circumferential in 
carcinoma; slit like in duct ectasia. 
Palpation of areola: Areola should be palpated for nodularity, thickening, 
ulcer, destruction. Paget’s disease can cause destruction of areola. 
Examination of an ulcer over breast: Ulcer if present over the breast lump, 
should be examined like any ulcer with inspection of floor, margin, edge, 
discharge; palpation for tenderness, induration, mobility, fixity. 
Examination of ipsilateral, regional axillary lymph nodes.  
Anterior/pectoral, central/medial, posterior, lateral, apical lymph nodes should 
be examined. 
Supraclavicular lymph nodes should be examined. 
Examination of opposite breast opposite axilla: 
Opposite axillary nodes are also examined. It may get involved through 
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retrograde spread from internal mammary nodes or through cutaneous 
lymphatics” 
Palpation of Axillary Lymph Nodes 
“Anterior/pectoral group of nodes are commonly involved nodes. Patient will 
be in sitting position. Raise the patient’s arm high and inspect the axilla. Place 
the patient’s forearm over examiner’s forearm. Palpate the relaxed axilla over 
pectoralis major muscle for any lymph nodes. Examiner will use his left hand to 
examine the nodes (of right axilla) and his right hand will be over patient’s left 
shoulder to support. 
Interpectoral nodes (Rotter’s) are also palpated similarly by insinuating the 
fingers between the two pectori. It signifies retrograde spread of the tumor. It is 
often difficult to palpate. 
Central/medial group of nodes are palpated in similar way like pectoral nodes 
but hand in the axilla is directed medially over the lateral chest wall and with 
gentle rolling movements using pulp of the finger. 
Lateral/humeral group of nodes are palpated with examiner’s right hand (for 
right axilla) with left hand placed over same side shoulder. 
Posterior/subscapular nodes are palpated with patient in sitting position and 
examiner standing behind the patient. By raising the arm and forearm of the 
patient from opposite side the posterior axillary fold is palpated between thumb 
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and fingers. 
Apical nodes are palpated (for right axilla) with left hand of the examiner 
placing high in the axilla with right hand supporting over the shoulder and 
supraclavicular region of the same side of the axilla. It is often difficult to 
palpate. 
Supraclavicular nodes are palpated using fingers over supraclavicular fossa by 
standing behind the patient who is asked to shrug the shoulder. 
Axillary nodes on opposite side are also examined. 
Opposite axilla can be examined by examiner standing on the same side by 
leaning over the patient or can be examined by standing on the opposite side. Its 
involvement signifies stage IV disease.” 
Levels of the axillary nodes (Berg’s levels): 
Level I—Below and lateral to the pectoralis minor muscle—anterior, lateral, 
posterior 
Level II—Behind the pectoralis minor muscle—central 
Level III—Above and medial to pectoralis minor muscle—apical 
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“Axillary tail of the Spence: It is the extension of the upper outer quadrant of 
breast across foramen Langer deep to deep fascia. Foramen Langer is an 
opening in deep fascia over outer aspect of the breast which allows part of 
breast tissue to extend under deep fascia. Axillary tail is located adjacent to 
outer border of the pectoralis major muscle. When it is involved by carcinoma it 
should be differentiated by pectoral node enlargement. Axillary tail will move 
along with main breast tissue whereas pectoral node will not move when breast 
is moved as it has got independent mobility. Axillary tail often extends over the 
lateral edge of the pectoralis major muscle up to axilla. 
Examination of arms for venous edema or lymphedema:  
Venous edema may be due to axillary vein compression by nodal mass. 
Lymphedema may be due to lymphatic block following nodal involvement. 
Lymphedema is mainly distal. It is gradual in onset and progressive. Venous 
edema is sudden in onset, with bluish discolouration over the skin, uniform in 
both distal and proximal aspect of the upper limb (forearm and arm). 
Examination for mediastinal node involvement: It is done by percussion. 
Initially percussion for liver dullness. Percussion is done one space above from 
lateral to medial, to look for widened mediastinal border. Mediastinal nodes are 
common in middle mediastinum. 
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Examination of respiratory system: It is done for secondaries—altered breath 
sounds, features of consolidation or pleural effusion are looked for. 
Examination of abdomen: To look for palpable nodular liver, Krukenberg 
tumor in ovaries in menstruating age group, and ascites. It is completed with 
digital examination of rectum (P/R), and per vaginal examination. 
Examination of pelvis, spine, long bones for any swelling/ 
tenderness/pathological fracture/restricted movements of spine, hips, etc. 
Examination of central nervous system to look for any neurological deficits 
following metastatic disease in the brain” 
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“Diagnosis: 
The presence or absence of carcinoma in a suspicious clinically or 
mammographically detected abnormality can only be reliably determined by 
tissue biopsy. An abnormal MRI does not reliably indicate the presence of 
cancer, and a non-worrisome MRI does not reliably exclude carcinoma. 
Available biopsy techniques include fine needle aspiration (FNAC), core needle 
biopsy, and excisional biopsy. Needle biopsy techniques (FNAC or core biopsy) 
are preferred because they are more cost-effective than surgical excision, and 
because most breast lesions are benign, they avoid a surgical scar and potential 
cosmetic deformity. FNAC is easily performed, but requires a trained 
pathologist for accurate specimen interpretation and does not reliably 
distinguish invasive cancer from DCIS, a particular drawback for non-palpable 
abnormalities, which are often DCIS. Core-cutting needle biopsy has many of 
the advantages of FNAC, but provides a histologic specimen suitable for 
interpretation by any pathologist, and facilitates ER, PR, and HER2 testing.” 
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Biomarkers 
Breast cancer biomarkers are of several types. Risk factor biomarkers are those 
associated with increased cancer risk. These include familial clustering and 
inherited germline abnormalities, proliferative breast disease with atypia, and 
mammographic densities. Exposure biomarkers are a subset of risk factors that 
include measures of carcinogen exposure such as DNA adducts. Surrogate 
endpoint biomarkers are biologic alterations in tissue that occur between cancer 
initiation and development. These biomarkers are used as endpoints in short-
term chemoprevention trials and include histologic changes, indices of 
proliferation, and genetic alterations leading to cancer. Prognostic biomarkers 
provide information regarding cancer outcome irrespective of therapy, whereas 
predictive biomarkers provide information regarding response to therapy. 
Candidate 
prognostic and predictive biomarkers and biologic targets for breast cancer 
include (a) indices of proliferation such as proliferating cell nuclear antigen 
(PCNA) and Ki-67; (b) indices of apoptosis and apoptosis modulators such as 
bcl-2 and the 
bax:bcl-2 ratio; (c) indices of angiogenesis such as vascular endothelial growth 
factor (VEGF) and the angiogenesis index; (d) 
growth factors and growth factor receptors such as human epidermal growth 
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factor receptor 2 (HER-2)/neu, epidermal growth 
factor receptor (EGFr), transforming growth factor, platelet-derived growth 
factor, and the insulin-like growth factor family; (e) 
the steroid hormone receptor pathway; (f) the cell cycle, cyclins, and cyclin-
dependent kinases; (g) the proteasome; (h) the 
COX-2 enzyme; (i) the peroxisome proliferator-activated receptors (PPARs); (j) 
tumor-suppressor genes such as p53; and (k) 
the mammalian target of rapamycin (mTOR) signaling pathway. 
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 Neoadjuvant chemotherapy (NCT) was initially used to treat 
inflammatory and locally advanced breast carcinoma and to improve local 
control, and if possible patient survival. More recently, this strategy has been 
extended to the management of patients with operable disease, eligible for 
mastectomy, mainly in order to increase the rate of breast conservation. 
Nowadays, it is established that positive hormone receptor (HR) status acts as a 
favorable prognostic factor, and also as a strong predictor of response to 
adjuvant hormonal therapy. However, in contrast to stable parameters such as 
human epidermal growth factor receptor (HER)-2 status modifications in HR 
status have been described in the literature. Aromatase levels and progesterone 
receptor (PR) levels have been shown to be modified in residual disease after 
induction chemotherapy in breast cancer treated by NCT (docetaxel) . Arpino et 
al. have shown that HR status of contralateral breast cancer is independent of 
the receptor status of the first primary in the absence of adjuvant tamoxifen. 
Moreover, Lower  in a retrospective study, found a discordant HR status in 30% 
of cases between the primary and metastatic tumors from the same individual. 
This discordance in HR status had an impact on the overall survival (OS) of 
these patients. Nicolini  found, in 10%–30% of cases, a conversion rate from 
estrogen receptor (ER)+ to ER− and from ER− to ER+ between the primary 
tumor and the metastatic relapse. 
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 The purpose of this study was to investigate the concordance rate of HR 
status between the initial biopsy and the tumor remaining after NCT. 
 Patient and tumor characteristics according to type of neoadjuvant 
chemotherapy 
 The absence of distant metastasis was confirmed by chest x-ray, bone 
scan, and liver ultrasound. HR status was re-evaluated, before and after NCT.  
Treatment Modalities 
 NCT breast cancer has already been summarized in detail from 
prospective phase II clinical trials; for most patients treatment was with 
protocols: AVCF (doxorubicin, Taxobel (docetaxel). Changes in pathological 
prognostic factors have been described .Patients received a median number of 
six cycles of NCT. Chemotherapy was administrated i.v. at 21- or 28-day 
intervals. After treatment, patients underwent appropriate surgery according to 
the size of their residual tumor. 
Determination of HR Status 
Tumor samples were compared when available for the analysis of HR status of 
the tumor. The first biopsy was a needle core performed before NCT. The 
second came from the remaining tumor at surgery. A centralized comparative 
evaluation of ER and PR status was realized by immunohistochemistry (IHC). 
56 
 
To ensure homogeneity of the HR results, HR status was retested on a new 
section for all patients. HR status was then reevaluated in a blinded fashion by 
two pathologists, on 420 patients. 
Scoring System for HR Status 
The HR status was considered as positive if either the ER or PR status, or both, 
were positive. The HR status was considered negative when both the ER and 
PR status were negative 
The 10% cutoff system is currently used and recommended in France. The 
cutoff value for positivity was 10% of invasive tumor cells with stained nuclei. 
Survival results were last updated in March 2006. Disease-free survival (DFS) 
was defined as the elapsed time between the date of first diagnosis and the date 
of first relapse (local, contralateral, and distant event), whatever this relapse 
might be. OS was the time between the date of initial diagnosis and the date of 
the last status report, with the patient being alive or dead, whatever the cause of 
death. Survival curves were established according to the Kaplan–Meier method. 
The log-rank test was used for univariate comparisons of survival endpoints. A 
stepwise Cox regression procedure was carried out to assess the relative 
influence of prognostic factors on OS and DFS.
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HISTORY OF NEOADJUVANT CHEMOTHERAPHY 
 Historically, women diagnosed with breast cancer were first 
recommended local therapy, with emphasis on surgical removal of breast tissue 
and loco-regional lymph nodes. Subsequently, results of multiple randomized 
clinical trials have demonstrated unequivocally that adjuvant chemotherapy 
improves disease-free and overall survival. Adjuvant chemotherapy is 
commonly recommended to women with stage 2 or 3 breast cancer and to those 
with high risk stage 1 disease. Given the improvements in survival outcomes 
observed with adjuvant chemotherapy, investigators from the National Surgical 
Adjuvant Breast and Bowel Project (NSABP) led by Dr. Bernard Fisher 
hypothesized that, compared to adjuvant chemotherapy, the administration of 
the same regimen in the neoadjuvant setting would improve survival outcomes 
by early elimination of micro metastatic systemic disease. Indeed, the 
hypothesis was supported by early animal studies demonstrating superior 
outcomes in mice receiving systemic therapy prior to surgical removal of a 
tumor . 
 One of the initial clinical trials testing the hypothesis, designated NSABP 
Trial B-18, was designed to determine whether the neoadjuvant combination of 
4 cycles of doxorubicin and cyclophosphamide (AC) would more effectively 
prolong disease-free and overall survival than the same chemotherapy given in 
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the adjuvant setting. Another objective was to determine if the neoadjuvant 
chemotherapy would permit a more conservative breast surgery and reduce the 
incidence of ipsilateral breast tumor recurrence by minimizing the tumor size. 
Survival outcomes were identical among the two groups, with hazard ratio (HR) 
0.93 (95% confidence interval [CI], 0.81 to 1.06; P=0.27) for disease-free 
survival and 0.99 (95% CI, 0.85 to 1.16; P=0.90) for overall survival. Although 
neoadjuvant chemotherapy did not improve disease-free and overall survival, a 
higher proportion of women who received neoadjuvant therapy were able to 
undergo breast conserving surgery compared to the adjuvant group (68% and 
60%, respectively, P=0.001). Therefore, a main goal of neoadjuvant 
chemotherapy is to enhance surgical options and breast conservation. Dozens of 
trials have demonstrated similar results and the administration of neoadjuvant 
chemotherapy has become an attractive approach to women with stage 2 or 3 
breast cancer who are not candidates for breast conservation. 
 Importantly, the response to therapy is a powerful individualized 
prognostic factor. Women who achieve a pathological complete response in the 
breast following neoadjuvant chemotherapy are expected to experience 
excellent disease-free and overall survival compared to women with large 
residual disease. In B-18, women achieving a pathological complete response in 
the breast had superior disease-free survival (DFS) and overall survival (OS) 
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compared to those who did not achieve a pathological complete response (DFS 
HR=0.47, P=0.0001; OS HR=0.32, P=0.0001)). 
 Different groups have used varied definitions of pathological complete 
response which may have indicated absence of invasive disease in the breast, or 
both in the breast and lymph nodes . Others have proposed more continuous 
definitions such as a residual stage or combination of anatomical and 
histopathological features. Regardless, in each of these reports, absence of 
disease in both the breast and lymph nodes provides the best overall outcome. 
 Investigations of neoadjuvant chemotherapy over the years have 
produced additional value by both providing data regarding selection of agents 
or combinations and the appropriate identification of patient populations most 
likely to benefit from the approach. 
  Women should be observed closely during treatment and if there is a 
concern for progressive disease they should be transitioned to an alternative 
regimen or to a local treatment. Finally, the neoadjuvant treatment approach has 
become an important vehicle for new drug and biomarker investigation. 
Response can be assessed clinically or with standard and functional imaging. 
Moreover, access to tumor tissue is relatively non-invasive and allows both for 
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assessment of biomarker modulation following standard or novel treatment and 
the study of drug mechanism of action. 
 Women should be informed that neoadjuvant chemotherapy may be 
associated with potential disadvantages. Initial studies raised concern that breast 
conserving surgery was associated with increased loco regional recurrence risk. 
However, newer studies suggest that with adequate free margins, the risk of 
loco regional recurrence is not higher in women administered neoadjuvant 
chemotherapy compared to those receiving the same regimen in the adjuvant 
setting. Another concern is that the inability to determine an accurate 
pathological stage may be a disadvantage of neoadjuvant chemotherapy. 
However, the knowledge of residual disease may provide a more personalized 
prognostic value. 
 Since disease-free and overall survival are equivalent when the same 
regimen is administered in the adjuvant or neoadjuvant setting, discussions with 
an individual woman should focus on the potential benefits and possible 
disadvantages she may encounter. Once neoadjuvant chemotherapy is initiated, 
women should be well informed of the goals of treatment, the required 
preoperative assessment, monitoring response, local treatment considerations, 
and post-treatment evaluation 
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SELECTION OF PATIENTS 
 Members of an International Consensus Expert Panel have suggested that 
neoadjuvant chemotherapy should be considered in any individual for whom 
adjuvant chemotherapy is indicated .Once a decision has been made to 
administer chemotherapy, the entire recommended chemotherapy regimen 
should be ideally delivered prior to the local therapy. Therefore, a careful 
staging evaluation must take place prior to initiation of treatment to assess the 
extent of the disease within the breast and regional lymph nodes, to exclude 
distant metastatic sites of disease, and to characterize the tumors, as described 
in Section 4. Initial clinical trials of neoadjuvant chemotherapy have generally 
included women with stage 2 or 3 disease regardless of their tumor 
characteristics. More recent understanding of tumor biology has led to 
refinement of the criteria of women who should be considered for neoadjuvant 
chemotherapy based on the likelihood of achieving a pathological complete 
response. Improvements in disease-free survival in those achieving pathological 
complete response were observed in luminal B/HER2-negative, HER2-
positive/non-luminal, and triple-negative breast cancer; but not in luminal A, or 
luminal B/HER2-positive tumors . Importantly, pathological complete response 
in HER2-positive (non-luminal) and triple-negative tumors was associated with 
excellent overall outcome. 
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 Women with stage 2 or 3 disease whose tumors do not express ER/PR or 
whose tumors are HER2-positive should be considered for neoadjuvant 
chemotherapy. Women whose tumors are low grade with a high expression of 
the hormone receptors and that are HER2-negative are less likely to respond to 
cytotoxic therapy and should be considered for primary surgery, especially 
when the nodes are clinically negative. Those women may not require 
chemotherapy or may be recommended a less aggressive systemic regimen. 
Women with a limited number of positive nodes may also be eligible for 
clinical trials randomly assigning them to chemotherapy versus no 
chemotherapy based on molecular characteristics. For example, in the S1007 
trial (RxPONDER) women with hormone receptor-positive, HER2-negative 
breast cancer with 1–3 positive nodes and a recurrence score of 25 or less are 
randomly assigned to standard adjuvant endocrine therapy with or without 
adjuvant chemotherapy). Of note, women with large hormone receptor-positive 
cancers may be candidates for neoadjuvant hormone therapy, an approach 
discussed elsewhere in this issue. 
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ROLE OF NEOADJUVANT CHEMOTHERAPHY 
 Neoadjuvant chemotherapy has traditionally been recommended to 
women with locally advanced breast cancer, being employed predominantly to 
downstage inoperable tumors and allow for definitive surgery. Current 
consensus opinion for use of preoperative chemotherapy recommends 
anthracycline- and taxane (paclitaxel)-based therapy. This recommendation is 
based on data from several prospective trials which suggest that neoadjuvant 
anthracycline- and taxane-based therapy is associated with the highest response 
rates . Multidisciplinary management of patients undergoing neoadjuvant 
therapy by an experienced team is essential in order to optimize the selection of 
patients, choice of systemic therapy, management of the axilla and surgical 
approach, as well as the decision to administer adjuvant radiation therapy. 
 As similar survival benefits have been demonstrated for the 
administration of chemotherapy before or after surgery, this approach is more 
frequently recommended to women with primary operable stage 2 or 3 disease. 
1. The preoperative period has been accepted as an important setting for 
evaluation of surrogate biomarkers for both response to therapy and the 
prediction of clinical outcome.. Tumor response to therapy can be assessed 
determination pathological response or by exploiting biochemical or 
67 
 
radiologic changes in malignant tissue prior to, during, and following 
neoadjuvant therapy. 
2. The most utilized surrogate predictor of long term outcome in neoadjuvant 
clinical trials is pathological complete response. Despite the varied 
definitions in trials completed to date, it has been consistently demonstrated 
that pathological complete response is associated with superior disease-free 
and overall survival. Women without residual invasive and noninvasive 
tumor cells in the breast and axillary nodes have substantially improved 
outcomes compared to women with similar stage and tumor characteristics 
and extensive residual disease. 
3.       Standard clinical & pathologic factors such as age, estrogen receptor 
or HER2 status,    grade, and proliferation index are already used 
routinely in clinical practice to determine the choice of therapy for those 
with  breast cancer . Chromosomal instability and PTEN loss modules 
were associated with an increased rate of pathological complete response 
with anthracycline with or without taxane-based neoadjuvant 
chemotherapy in ER-negative/HER2-negative and ER-positive/HER2-
negative cancers 
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PATHOLOGICAL RESPONSE 
4. pCR is defined as the absence of residual invasive cancer on hematoxylin 
and eosin evaluation of the complete resected breast specimen and all 
sampled regional lymph nodes following the completion of neoadjuvant 
systemic therapy (ie, ypT0/Tis ypN0 in the current AJCC staging system) or 
5. pCR is defined as the absence of residual invasive and in situ cancer on 
hematoxylin and eosin evaluation of the complete resected breast specimen 
and all sampled regional lymph nodes following the completion of 
neoadjuvant systemic therapy (ie, ypT0 ypN0 in the current American Joint 
Committee on Cancer [AJCC] staging system). 
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luminal A–like tumors. 
ER positive and/or PR positive, HER2 negative, grade 1 or 2. 
Luminal B/HER2-negative–like tumors. 
ER positive and/or PR positive, HER2 negative, grade 3. 
Luminal B/HER2-positive–like tumors. 
ER positive and/or PR positive, HER2 positive, all grades. 
HER2-positive (nonluminal) –like tumors. 
        ER negative and PR negative, HER2 positive, all grades. 
TN tumors. 
ER negative, PR negative, HER2 negative, all grades. 
Histologic type, tumor grade, and ER, PR, and HER2 status were assessed in 
the primary tumor core biopsy 
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Neoadjuvant chemotheraphy 
 Neoadjuvant chemotherapy has traditionally been recommended to 
women with locally advanced breast cancer, being employed predominantly to 
downstage inoperable tumors and allow for definitive surgery. Current 
consensus opinion for use of preoperative chemotherapy recommends 
anthracycline- and taxane (paclitaxel)-based therapy. This recommendation is 
based on data from several prospective trials which suggest that neoadjuvant 
anthracycline- and taxane-based therapy is associated with the highest PCR 
rates . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
72 
 
 
RESULTS 
AGE No Of Cases Percentage 
<40 13 26 
41 – 50 16 32 
51 – 60 13 26 
>60 8 16 
Total 50 100 
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Diagnosis No Of Cases Percentage 
Left  ca breast 20 40 
Right Ca breast 30 60 
Total 50 100 
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Stage No Of Cases Percentage 
T3N0M0 9 18 
T3N1M0 17 34 
T3N2M0 3 6 
T4N1M0 16 32 
T4N2M0 5 10 
Total 50 100 
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ER / PR No Of Cases Percentage 
Positive 18 36 
Negative 32 64 
Total 50 100 
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HER 2 No Of Cases Percentage 
Positive 8 16 
Negative 42 84 
Total 50 100 
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Pathological Stage No Of Cases Percentage 
ypT0N0M0 25 50 
ypT1N0M0 4 8 
ypT1N1M0 1 2 
ypT2N0M0 6 12 
ypT2N1M0 3 6 
ypT3N0M0 1 2 
ypT3N1M0 3 6 
ypT3N2M0 2 4 
ypT4N1M0 4 8 
ypT4N2M0 1 2 
Total 50 100 
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Response No Of Cases Percentage 
pCR 25 50 
pNR 9 18 
pPR 16 32 
Total 50 100 
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ER  / PR  VS RESPONSE 
 
ER  / PR  VS 
RESPONSE PCR PNR PPR 
POSITIVE  (18) 1 9 8 
NEGATIVE (32) 24 0 8 
TOTAL 25 9 16 
 
 
 
ER / PR VS RESPONSE  
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HER2   VS 
RESPONSE PCR PNR PPR 
Positive 2 5 1 
Negative 23 4 15 
Total 25 9 16 
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RESEARCH PROPOSAL 
AIM &OBJECTIVES 
To know the association between hormone receptor status and 
pathological response in carcinoma breast after neo adjuvant 
chemotheraphy. 
To quantify receptor status for chemotheraphy dose adjustment 
1. ELIGIBILITY CRITERIA :  
• INCLUSION CRITERA : 1.PATIENTS OF REPRODUCTIVE AGE 
GROUP(20-60     YRS) DIAGNOSED AS CARCINOMA BREAST  
2. LUMP SIZE MORE THAN 5CMS 
3.  NO DISTAL METASTASIS               
4. PATIENTS CONSENTED FOR INCLUSION IN THE STUDY 
ACCORDING TO THE DESIGNATED PROFORMA  
• EXCLUSION CRITERIA : 1.ALL THE PATIENTS 
PRESENTING WITH LUMP SIZE LESS THAN 5CM 
2.AGE MORE THAN 60 YEARS 
 3.WITH METASTASIS PATIENTS  
4.PREGNANCY 
ARE NOT CONSENTED FOR INCLUSION IN THE STUDY  
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3.SOURCE OF DATA : ALL PATIENTS DIAGNOSED TO HAVE 
CARCINOMA BREAST DISEASE COMING UNDER THE INCLUSION 
CRITERIA AT GOVT RAJAJI HOSPITAL, MADURAI  
4.METHOD OF COLLECTION OF DATA : DETAILS OF CASES, FULL 
HISTORY, CLINICAL EXAMINATION & SIGNS AND SYMPTOMS OF 
PATIENTS COMING UNDER THE INCLUSION CRITERIA & THEIR 
ER/PR STATUS 
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CLINICAL APPLICATION 
Patient selected for study was undergone trucut biopsy and sent for HPE and 
ER/PR STATUS . 
Quantification of hormone receptor status 
After confirming that its malignancy, neoadjuvant chemotheraphy is given 
After neoadjuvant chemo patient is taken for surgery 
Post op HPE is studied 
• Good clinical response is absence of residual tumor cells in specimen. 
• Partial response is down staging of tumor (ductal to carcinoma in situ) 
• Equcivocal response no response or no change in status. 
• Poor response tumor size increased 
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DISCUSSION 
 Nowadays, Neo adjuvant therapy remains the most efficient adjuvant 
treatment for HR-negative breast cancer, with a gain in DFS of around 15% at 
15 years in a meta-analysis database. Patients treated with this therapy are 
traditionally selected by an assessment of their HR status. It is generally 
accepted that an HR negative status predicts response to neo adjuvant therapy. 
 50 patients with breast cancer included in this study, preoperative  core 
needle biopsy done and hormone receptor status assessed . neoadjuvant 
chemotheraphy given after hormone receptor status. 
 Right breast involved in 60 % of cases and upper outer quadrant most 
commonly involved. Infiltrating ductal carcinoma was the underlying pathology 
in all cases. 
 Hormone receptor negativity was seen in more no of patients . Dose 
adjustments in chemotheraphy is done . After completing chemotheraphy 
patient is taken for surgery depending upon residual tumor. ER+PR-HER2+, 
ER-PR+HER2+ and ER-PR+HER2-. In the neoadjuvant setting the 
pathological complete response (pCR) to primary chemotherapy (PC) is 
associated to negativity for ER and PR receptors, and in patients (Patients) with 
HER2 + BC, the addition of trastuzumab to PC increasing the rate of pCR. The 
aims of this study were to determine the pCR of PC with anthracyclines (A) and 
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taxanes (T) in Patients with LABC grouped according to ER, PR and HER2 
status. 
 Methods: Patients with LABC treated with PC including A and T were grouped 
according to ER, PR and HER2 status, and the pCR rate were analyzed using 
the chi-squared test and correlations with a p value of ≤0,05 were considered 
statistically significant 
.  
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CONCLUSION 
 
 We conclude that pCR  is associated with highly favorable outcome.  
ypN+ residuals only are associated with increased relapse risk and should 
therefore no longer be considered as pCR. Extent of residual disease and 
evidence of regression provide helpful additional prognostic information. pCR 
is a suitable surrogate end point for patients with HER2-positive (nonluminal), 
TN, and luminal B/HER2-negative tumors but not for luminal B/HER2-positive 
and luminal A tumors. 
 In this study 50 post mastectomy specimens were collected hormone 
receptor negativity is seen in most patients . Pathological response assessed. 
Dose adjustment in chemotheraphy is also done. 
    pCR is seen 50% of patients  
 pPR is seen in 32% of patients 
  pNR is seen in 18% of patients 
  We conclude that neoadjuvant chemotheraphy is recommended for 
patients with hormone receptor negative status , which gives pCR . Thereby 
enhances patients OS & DFS.   
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 Standard chemotheraphy dose  should be administered to patients 
otherwise response will be poor . 
 In patients with LABC to group Breast Cancer according to ER, PR and 
HER2 status can help to predict pCR to Primary Chemotheraphy 
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